Patents by Inventor Peter J. Facchini

Peter J. Facchini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carboxylated psilocybin derivatives and methods of using
    Patent number: 12605361
    Abstract: Disclosed are novel carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a carboxyl or Carboxylic acid derivative containing compound.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: April 21, 2026
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
    Publication number: 20260103442
    Abstract: Disclosed are novel aminated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The aminated psilocybin derivative compounds may be chemically synthesized.
    Type: Application
    Filed: June 11, 2025
    Publication date: April 16, 2026
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • SUBSTITUTED N-PROPYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES
    Publication number: 20260078102
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably substituted N-propylamine fused heterocyclic mescaline derivatives, including substituted N-propylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Application
    Filed: June 5, 2025
    Publication date: March 19, 2026
    Inventors: Kaveh Matinkhoo, David James Press, Glynnis Elizabeth Jensen, Ye Cai, Jillian M. Hagel, Peter J. Facchini
  • N-heterocycle substituted tryptamine derivatives and methods of using
    Patent number: 12577232
    Abstract: Disclosed are novel N-heterocycle-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: May 29, 2025
    Date of Patent: March 17, 2026
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: David James Press, Glynnis Elizabeth Jensen, Kaveh Matinkhoo, Jessica Bik-Jing Lee, Jillian M. Hagel, Peter J. Facchini
  • SUBSTITUTED ETHYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES
    Publication number: 20260062399
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably substituted ethylamine fused heterocyclic mescaline derivatives, including substituted ethylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Application
    Filed: November 6, 2025
    Publication date: March 5, 2026
    Inventors: Kaveh Matinkhoo, David James Press, Jessica Bik-jing Lee, Ye Cai, Jillian M. Hagel, Peter J. Facchini
  • Substituted ethylamine fused heterocyclic mescaline derivatives
    Patent number: 12492179
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably substituted ethylamine fused heterocyclic mescaline derivatives, including substituted ethylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Grant
    Filed: December 15, 2023
    Date of Patent: December 9, 2025
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Kaveh Matinkhoo, David James Press, Jessica Bik-jing Lee, Ye Cai, Jillian M. Hagel, Peter J. Facchini
  • C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING
    Publication number: 20250352512
    Abstract: Disclosed are novel C4-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same, including C4-ether-substituted tryptamine derivative compounds, C4-carbonic ester-substituted tryptamine derivative compounds, C4-polyether substituted tryptamine derivative compounds, and C4-phosphate substituted tryptamine derivative compounds. The pharmaceutical formulations may be used to treat psychiatric disorders.
    Type: Application
    Filed: March 17, 2023
    Publication date: November 20, 2025
    Inventors: Kaveh MATINKHOO, David James PRESS, Ye CAI, Glynnis Elizabeth JENSEN, Jessica Bik-Jing LEE, Jillian M. HAGEL, Peter J. FACCHINI
  • Fused heterocyclic mescaline derivatives
    Patent number: 12428408
    Abstract: Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Grant
    Filed: August 4, 2023
    Date of Patent: September 30, 2025
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Peter J. Facchini, Jillian M. Hagel, Chang-Chun Ling, Ye Cai, David James Press, Glynnis Elizabeth Jensen, Jessica Bik-Jing Lee, Kaveh Matinkhoo
  • N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING
    Publication number: 20250289805
    Abstract: Disclosed are novel N-heterocycle-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Application
    Filed: May 29, 2025
    Publication date: September 18, 2025
    Inventors: David James PRESS, Glynnis Elizabeth JENSEN, Kaveh MATINKHOO, Jessica Bik-Jing LEE, Jillian M. HAGEL, Peter J. FACCHINI
  • Aminated psilocybin derivatives and methods of using
    Patent number: 12378195
    Abstract: Disclosed are novel aminated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The aminated psilocybin derivative compounds may be chemically synthesized.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: August 5, 2025
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Substituted n-propylamine fused heterocyclic mescaline derivatives
    Patent number: 12358885
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably substituted N-propylamine fused heterocyclic mescaline derivatives, including substituted N-propylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Grant
    Filed: November 17, 2023
    Date of Patent: July 15, 2025
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Kaveh Matinkhoo, David James Press, Glynnis Elizabeth Jensen, Ye Cai, Jillian M. Hagel, Peter J. Facchini
  • C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING
    Publication number: 20250214934
    Abstract: Disclosed are novel C4-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same, including C4-ether-substituted tryptamine derivative compounds, C4-carbonic ester-substituted tryptamine derivative compounds, C4-polyether substituted tryptamine derivative compounds, and C4-phosphate substituted tryptamine derivative compounds. The pharmaceutical formulations may be used to treat psychiatric disorders.
    Type: Application
    Filed: March 17, 2023
    Publication date: July 3, 2025
    Inventors: Kaveh MATINKHOO, David James PRESS, Ye CAI, Glynnis Elizabeth JENSEN, Jessica Bik-Jing LEE, Jillian M. HAGEL, Peter J. FACCHINI
  • C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING
    Publication number: 20250206701
    Abstract: Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Application
    Filed: August 22, 2022
    Publication date: June 26, 2025
    Inventors: Jillian M. HAGEL, Kaveh MATINKHOO, Peter J. FACCHINI
  • N-heterocycle substituted tryptamine derivatives and methods of using
    Patent number: 12338231
    Abstract: Disclosed are novel N-heterocycle-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: June 24, 2024
    Date of Patent: June 24, 2025
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: David James Press, Glynnis Elizabeth Jensen, Kaveh Matinkhoo, Jessica Bik-Jing Lee, Jillian M. Hagel, Peter J. Facchini
  • C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING
    Publication number: 20250197351
    Abstract: Disclosed are novel C4-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders through the modulation of various receptors, such as 5-HT1A receptor, a 5-HT2A receptor, a 5-HT1B receptor, a 5-HT2B receptor, a 5-HT3A receptor, an ADRA1 A receptor, an ADRA2A receptor, CHRM1 receptor, a CHRM2 receptor, a CNR1 receptor, a DRD1 receptor, a DRD2S receptor, or an OPRD1 receptor.
    Type: Application
    Filed: August 11, 2022
    Publication date: June 19, 2025
    Inventors: Jillian M. HAGEL, Ye CAI, Kaveh MATINKHOO, David James PRESS, Glynnis Elizabeth JENSEN, Peter J. FACCHINI
  • C1-SUBSTITUTED ISOPROPYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES
    Publication number: 20250129036
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably C1-substituted isopropylamine fused heterocyclic mescaline derivatives, including C1-substituted isopropylamine fused dioxolane and fused dioxane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Application
    Filed: December 16, 2024
    Publication date: April 24, 2025
    Inventors: Kaveh Matinkhoo, David James Press, Glynnis Elizabeth Jensen, Jillian M. Hagel, Peter J. Facchini
  • HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
    Publication number: 20250100967
    Abstract: Disclosed are novel hydroxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced synthetically or biosynthetically.
    Type: Application
    Filed: December 6, 2024
    Publication date: March 27, 2025
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
    Publication number: 20250057861
    Abstract: Disclosed are novel halogenated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced using a biosynthetic system which comprises cells comprising a psilocybin biosynthetic enzyme complement.
    Type: Application
    Filed: October 8, 2024
    Publication date: February 20, 2025
    Inventors: Jillian M. Hagel, Peter J. Facchini
  • MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING
    Publication number: 20250025483
    Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.
    Type: Application
    Filed: September 19, 2024
    Publication date: January 23, 2025
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • C1-substituted isopropylamine fused heterocyclic mescaline derivatives
    Patent number: 12195439
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably C1-substituted isopropylamine fused heterocyclic mescaline derivatives, including C1-substituted isopropylamine fused dioxolane and fused dioxane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: January 14, 2025
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Kaveh Matinkhoo, David James Press, Glynnis Elizabeth Jensen, Jillian M. Hagel, Peter J. Facchini